Nexalin Technology, Inc. Receives Nasdaq Continued-Listing Notice

What Happened Nexalin Technology, Inc. (NXL) filed an 8-K stating that on September 25, 2026 the Nasdaq Hearings Panel granted the Company’s request to remain listed on The Nasdaq Capital Market, subject to conditions. The Panel requires Nexalin to demonstrate compliance with the minimum bid price requirement by September 28, 2026 and to meet the $2,500,000 stockholders’ equity requirement by January 4, 2027. The Panel also imposed an additional requirement that the Company demonstrate a closing bid price of $1.00 or greater for at least 20 consecutive trading sessions under Nasdaq Listing Rule 5815(c)(4). As previously disclosed, Nasdaq had issued delisting notices in July and August 2026 for failure to meet the minimum bid price and stockholders’ equity standards.

Key Details

• Nasdaq Panel granted conditional continued listing on September 25, 2026.
• Must meet the minimum bid price requirement by September 28, 2026.
• Must meet the $2,500,000 stockholders’ equity requirement by January 4, 2027.
• Must show a closing bid of $1.00+ for a minimum of 20 consecutive trading sessions per Rule 5815(c)(4).
• Common stock will remain listed and traded during the exception period, but failure to satisfy conditions will subject the shares to delisting.

Why It Matters This filing notifies investors that Nexalin faces near-term Nasdaq compliance deadlines tied to share price and equity levels. Remaining listed preserves trading access and liquidity, but failure to meet the Panel’s conditions would lead to delisting and potentially reduced marketability of the common stock. The company says it intends to take steps to comply, but the filing makes clear there is no assurance it will meet those requirements within the deadlines.